newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1